Table 3—

Percentage of symptom-free days after 12 weeks of treatment

ParameterTreatmentMeanDifference compared with placebo
%95% CIp-value
Nights with no sleep disturbance %Formoterol 4.5 µg50.673.12−3.12–9.370.3267
Formoterol 9 µg48.611.06−5.25–7.380.7406
Formoterol 18 µg54.526.970.79–13.150.0271
Placebo47.55
Days with no breathlessness %Formoterol 4.5 µg17.382.51−2.94–7.970.3659
Formoterol 9 µg21.436.571.04–12.100.0199
Formoterol 18 µg22.437.572.16–12.980.0062
Placebo14.86
Days with no cough %Formoterol 4.5 µg29.923.26−2.48–9.000.2651
Formoterol 9 µg30.844.18−1.64–10.000.1591
Formoterol 18 µg30.493.83−1.86–9.530.1869
Placebo26.66
Days with no chest tightness %Formoterol 4.5 µg40.864.25−2.02–10.530.1838
Formoterol 9 µg48.2611.655.29–18.010.0003
Formoterol 18 µg43.867.251.02–13.480.0225
Placebo36.6
Symptom-free days %Formoterol 4.5 µg8.01.4−2.7–5.40.5094
Formoterol 9 µg11.34.70.6–8.80.0249
Formoterol 18 µg12.35.71.6–9.70.0057
Placebo6.6
  • Data are presented as adjusted geometric means unless otherwise stated

  • CI: confidence interval